Tucci A - Search Results

1

Clinical characteristics and risk factors for mortality in hematologic patients affected by COVID-19.

Cattaneo C, Daffini R, Pagani C, Salvetti M, Mancini V, Borlenghi E, D'Adda M, Oberti M, Paini A, De Ciuceis C, Barbullushi K, Cancelli V, Belotti A, Re A, Motta M, Peli A, Bianchetti N, Anastasia A, Dalceggio D, Roccaro AM, Tucci A, Cairoli R, Muiesan ML, Rossi G. Cattaneo C, et al. Among authors: tucci a. Cancer. 2020 Dec 1;126(23):5069-5076. doi: 10.1002/cncr.33160. Epub 2020 Sep 10. Cancer. 2020. PMID: 32910456 Free article.

2

Transformation of a MGUS to overt multiple myeloma: the possible role of a pituitary macroadenoma secreting high levels of insulin-like growth factor 1 (IGF-1).

Tucci A, Bonadonna S, Cattaneo C, Ungari M, Giustina A, Guiseppe R. Tucci A, et al. Leuk Lymphoma. 2003 Mar;44(3):543-5. doi: 10.1080/1042819021000037895. Leuk Lymphoma. 2003. PMID: 12688330

3

The development of more than one histologic type of lymphoma in the same patient is frequent and confers a worse prognosis.

Tucci A, Motta M, Ungari M, Ruggeri G, Crippa C, Borlenghi E, Ubiali A, Facchetti F, Rossi G. Tucci A, et al. Haematologica. 2005 Mar;90(3):348-52. Haematologica. 2005. PMID: 15749667

4

Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments.

Cattaneo C, Spedini P, Casari S, Re A, Tucci A, Borlenghi E, Ungari M, Ruggeri G, Rossi G. Cattaneo C, et al. Among authors: tucci a. Leuk Lymphoma. 2006 Jun;47(6):1013-7. doi: 10.1080/10428190500473113. Leuk Lymphoma. 2006. PMID: 16840190

5

Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma.

Sacchi S, Pozzi S, Marcheselli R, Federico M, Tucci A, Merli F, Orsucci L, Liberati M, Vallisa D, Brugiatelli M; Italian Lymphoma Study Group. Sacchi S, et al. Among authors: tucci a. Cancer. 2007 Jul 1;110(1):121-8. doi: 10.1002/cncr.22740. Cancer. 2007. PMID: 17503433 Free article. Clinical Trial.

6

A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy.

Tucci A, Ferrari S, Bottelli C, Borlenghi E, Drera M, Rossi G. Tucci A, et al. Cancer. 2009 Oct 1;115(19):4547-53. doi: 10.1002/cncr.24490. Cancer. 2009. PMID: 19562776 Free article.

7

Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients.

Zinzani PL, Rossi G, Franceschetti S, Botto B, Di Rocco A, Cabras MG, Petti MC, Stefoni V, Broccoli A, Fanti S, Pellegrini C, Montini GC, Gandolfi L, Derenzini E, Argnani L, Fina M, Tucci A, Bottelli C, Pileri S, Baccarani M. Zinzani PL, et al. Among authors: tucci a. Clin Cancer Res. 2010 Aug 1;16(15):3998-4004. doi: 10.1158/1078-0432.CCR-10-0162. Epub 2010 Jun 11. Clin Cancer Res. 2010. PMID: 20542986 Free article. Clinical Trial.

8

Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation (FIL).

Tucci A, Martelli M, Rigacci L, Riccomagno P, Cabras MG, Salvi F, Stelitano C, Fabbri A, Storti S, Fogazzi S, Mancuso S, Brugiatelli M, Fama A, Paesano P, Puccini B, Bottelli C, Dalceggio D, Bertagna F, Rossi G, Spina M; Italian Lymphoma Foundation (FIL). Tucci A, et al. Leuk Lymphoma. 2015 Apr;56(4):921-6. doi: 10.3109/10428194.2014.953142. Epub 2014 Oct 9. Leuk Lymphoma. 2015. PMID: 25110825

9

Peri-operative complications and hematologic improvement after first-line splenectomy for splenic marginal zone lymphoma.

Pata G, Damiani E, Bartoli M, Solari S, Anastasia A, Pagani C, Tucci A, Ragni F. Pata G, et al. Among authors: tucci a. Leuk Lymphoma. 2016;57(6):1467-70. doi: 10.3109/10428194.2015.1092529. Epub 2015 Oct 15. Leuk Lymphoma. 2016. PMID: 26373930 No abstract available.

10

Primary cutaneous non-Hodgkin lymphoma: results of a retrospective analysis in the light of the recent ILROG guidelines.

Pedretti S, Urpis M, Leali C, Borghetti P, Baushi L, Sala R, Tucci A, Greco D, Pasinetti N, Triggiani L, Rossi G, Calzavara-Pinton P, Magrini SM, Buglione M. Pedretti S, et al. Among authors: tucci a. Tumori. 2018 Oct;104(5):394-400. doi: 10.5301/tj.5000606. Epub 2018 May 8. Tumori. 2018. PMID: 28218382

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

453 results

Search Page